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prostate cancer cell migration and invasion
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Abstract
Background: Carcinoma cells must circumvent the normally suppressive signals to disseminate. While often
considered ‘stop’ signals for adherent cells, CXCR3-binding chemokines have recently been correlated positively
with cancer progression though the molecular basis remains unclear.
Results: Here, we examined the expression and function of two CXCR3 variants in human prostate cancer biopsies
and cell lines. Globally, both CXCR3 mRNA and protein were elevated in localized and metastatic human cancer
biopsies compared to normal. Additionally, CXCR3A mRNA level was upregulated while CXCR3B mRNA was
downregulated in these prostate cancer specimens. In contrast to normal prostate epithelial cells (RWPE-1), CXCR3A
was up to half the receptor in the invasive and metastatic DU-145 and PC-3 prostate cancer cells, but not in the
localized LNCaP cells. Instead of inhibiting cell migration as in RWPE-1 cells, the CXCR3 ligands CXCL4/PF4 and
CXCL10/IP10 promoted cell motility and invasiveness in both DU-145 and PC-3 cells via PLCb3 and μ-calpain
activation. CXCR3-mediated diminution of cell motility in RWPE-1 cells is likely a result of cAMP upregulation and
m-calpain inhibition via CXCR3B signal transduction. Interestingly, overexpression of CXCR3B in DU-145 cells
decreased cell movement and invasion.
Conclusion: These data suggest that the aberrant expression of CXCR3A and down-regulation of CXCR3B may
switch a progression “stop” to a “go” signal to promote prostate tumor metastasis via stimulating cell migration
and invasion.
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Introduction
Prostate cancer is the most frequently diagnosed cancer
and a leading cause of cancer death in men, with the
mortality and morbidity being mainly due to tumor
invasion and metastasis [1]. Current therapies are only
effective against localized prostate cancer; once the
tumor invades and disseminates to surrounding tissues
or metastasizes to distance sites, current treatments only
slightly prolong patient survival [1-4]. Thus, patient ben-
efit awaits rational approaches targeting the molecular
underpinnings of this transition to tumor dissemination.
Tumor invasion and metastasis requires, among other
cell behaviors, enhanced cancer cell motility [5-10].
Many studies have found that invasive prostate cancer
cells have enhanced motility in response to paracrine,
autocrine and matrix-derived pro-migratory signals
[10-14]. Thus, these signals and the receptors and intra-
cellular signaling pathways through which they actuate
motility represent potential targets. However, the myriad
such factors and numerous pathways make this type of
‘attenuative’ approach difficult and/or short-lived.
A novel potential approach to limit tumor dissemina-
tion would be to re-instate the physiological ‘stop’ sig-
nals that keep normal and dysplastic epithelial cells
localized. Work in this area has mainly focused on
downregulation of cell-cell adhesion molecules such as
E-cadherin during the acquisition of EMT or upregula-
tion of matrix metalloproteinases [10,12,15,16]. More
recently, paracrine signals have been recognized as pro-
viding additional inhibition to migration. The family of
chemokines that bind to the CXCR3 receptor has been
shown to inhibit the motility of adherent cells such as
fibroblasts and endothelial cells, even while being che-
motactic for leukocytes [17-19].
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CXCR3, a receptor for ELR-negative CXC chemokines,
is activated by specific binding of the ligands, CXCL4/
PF4, CXCL9/MIG, CXCL10/IP10, CXCL11/IP9/I-TAC,
resulting in diverse cellular responses, including chemo-
tactic migration and cell proliferation, or inhibition of
migration and even endothelial death depending on the
cell type [20]. This diversity of cell behaviors is
explained, in part, by the presence of two splice variants
of CXCR3, CXCR3A and CXCR3B; CXCR3B contains a
longer extracellular domain at the N-terminus [19].
CXCR3A mainly functions in the chemotactic activity
on activated T lymphocytes and Natural Killer (NK)
cells [21,22]. Additionally, CXCR3A has also been
shown to promote cell proliferation [19]. However,
CXCR3B, primarily found expressed on fibroblasts,
endothelial and epithelial cells, inhibits cell migration
and endothelial apoptosis [18,19]. Some studies have
suggested that CXCR3A and CXCR3B play reciprocal
roles through different G-protein coupling and trigger
distinct signaling transduction pathways [19,23,24],
though there is some evidence for overlap in signaling
cascades with differential cellular outcomes being the
integration of signaling and the cell milieu [25,26].
Thus, differential responsiveness of carcinoma cells may
be due to either the cellular milieu or the CXCR3 iso-
form presentation.
CXCR3 expression is ubiquitous, though regulated in
some cell types. Interestingly, increased express has
been shown to positively correlate with human breast,
colon, renal, and prostate cancer [27-35]. Several groups
have reported that CXCR3 expression is linked to
breast, colon, osteosarcoma and melanoma cell metasta-
sis by regulating cell proliferation and/or cell migration
in murine models [31,34-38]. However, these studies did
not account for isoform usage since the CXCR3B iso-
form was identified only recently, and isolated detection
of CXCR3A is difficult due to almost complete overlap
with CXCR3B. A hint that the isoform distribution may
be important in tumor progression was provided by a
study in renal carcinomas in which treatment with calci-
neurin inhibitors results in bigger tumors in nude mice
secondary to downregulation of CXCR3B; in actuality
increased CXCR3B expression correlates with tumor
necrosis in renal cell carcinoma [30,32]. This may indi-
cate that the isoform normally expressed on epithelial
cells, CXCR3B, can be a tumor suppressive signal. How-
ever, these data also call for a more nuanced under-
standing of CXCR3 signaling in carcinoma progression,
to clarify the seemingly contradictory findings.
Herein, we dissect CXCR3 functioning in prostate car-
cinomas and derived cell lines. Our studies for the first
time demonstrated that both CXCR3 mRNA and pro-
tein expression was upregulated in human localized
prostate cancer and metastatic prostate cancer. More
importantly, CXCR3 splice variants exhibited different
mRNA expression profile-CXCR3A mRNA level was
high and CXCR3B mRNA was low in prostate cancer
compared to normal prostate. In addition, CXCR3B, the
dominant CXCR3 splice variant in normal prostate
epithelial cells (RWPE-1), was replaced in part by
CXCR3A in invasive and metastatic prostate cancer cell
lines (DU-145 and PC-3) and promoted cell motility
and invasiveness in vitro. This increase of prostate can-
cer cell migration and invasion was not only a result of
PLCb3 activation by CXCR3A, but also required down-
regulation of the strength of inhibitory signal via
CXCR3B. Restoring higher CXCR3B expression in DU-
145 cells significantly blocked CXCR3-chemokine-
induced cell movement and invasion. These in vitro
findings suggest that the aberrant expression of
CXCR3A and down-regulation of CXCR3B play an
important role in promoting prostate tumor invasion
and metastasis via subverting an anti-migratory to a
pro-migratory signal.
Results
CXCR3 and its splice variant expression in human
prostate carcinoma tissues
To study CXCR3 expression in human prostate carci-
nomas, a human tissue microarray was generated with
samples from the University of Pittsburgh Tumor Tis-
sue Bank. Thirty (30) normal prostate tissue, 92 pros-
tate cancer tissue and 12 metastatic prostate cancer
tissue were analyzed. In normal prostate tissue, CXCR3
was primarily expressed in all gland epithelial cells and
in some stromal cells (Figure 1A). In primary prostate
cancer samples, somewhat upregulated CXCR3 staining
was observed which was quantified by the percentage
of positive-stained cells (Figure 1B). This result was
further confirmed by paired-sample comparison (Figure
1C). An even higher percentage of positive cells was
markedly seen in metastatic prostate cancer tissue
(Figure 1B). However, in a survey across an admittedly
limited number of specimens, the increases in CXCR3
expression appeared to be independent of the target
organ of the metastases (Additional file 1). Examining
single cells, CXCR3 was predominantly on the cell
membrane in normal prostate tissue and primary carci-
nomas but this localization was replaced with a whole
cell stain in metastatic prostate cancer tissue (Figure
1A, enlarged boxes). Additionally, the result from in
situ hybridization targeting CXCR3 in 5 normal pros-
tate, 6 localized prostate cancer and 6 metastatic pros-
tate cancer samples showed that CXCR3 mRNA
expression significantly upregulated in localized and
metastatic prostate cancer patients (Figure 2), which
was consistent with CXCR3 protein expression profile
in prostate cancer.
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The two splice isoforms of CXCR3 have been reported
to play different roles in cellular function regulation;
therefore, CXCR3A and CXCR3B expression patterns
were examined in human prostate by in situ hybridiza-
tion (Figure 2A). Interestingly, CXCR3A mRNA was
increased while CXCR3B mRNA was decreased in the
prostate cancer samples compared to normal prostate
controls (Figure 2B), suggesting that the switch of
CXCR3 isoform expression may play an important
role in prostate cancer dissemination, invasion and
metastasis.
Prostate carcinoma cell lines express CXCR3A in contrast
to normal prostate epithelial cells
To study CXCR3 and its splice variant function in pros-
tate cancer, CXCR3 expression was first examined in
three commonly studied prostate cancer cell lines, DU-
145, PC-3 and LNCaP. DU-145 and PC-3 cell lines are
both androgen-insensitive invasive and metastatic in
murine xenograft models while LNCaP is androgen-sen-
sitive and remains localized upon orthotopic inoculation,
even though all were derived from prostate cancer
metastases. Compared to normal prostate epithelial cells
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Figure 1 CXCR3 expression and localization in prostate tumor tissues. (A) CXCR3 localization in human normal prostate, localized and
metastatic prostate cancer. The insets are at higher magnification to show the cellular localization of CXCR3 in the boxed areas. Pictures are
representative among the samples. Bar: 100 μm. (B) and (C) CXCR3 was upregulated in human localized and metastatic prostate cancer tissue. (B)
Box plot of CXCR3 expression in human normal prostate, localized and metastatic prostate cancer by percentage of CXCR3-positive cells (*P <
0.01). (C) Quantification of CXCR3 expression in paired normal and cancerous prostate samples (P < 0.02).
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Figure 2 mRNA expression of CXCR3 isoforms in prostate tumor tissues. (A) CXCR3, CXCR3A and CXCR3B mRNA expression in human
normal prostate, localized and metastatic prostate cancer. The inserts are the high magnification pictures. Bar: 10 μm. (B) Quantification of
CXCR3, CXCR3A andCXCR3B mRNA expression as shown in human normal prostate, localized and metastatic prostate cancer. Signal intensity was
measured by imageJ and the signal intensities of normal tissues were set as 1 in each group.
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Figure 3 CXCR3 expression in human normal and prostate cancer cell lines. (A) mRNA expression of CXCR3 in RWPE-1, DU-145, PC-3 and
LNCaP cells. CXCR3 RNA was normalized to GAPDH RNA levels for that cell line, prior to normalizing to RWPE-1 cells. Histograms represent
mean values (+/-s.d.) of more than three separate experiments. (B) mRNA expression of CXCR3A and CXCR3B in RWPE-1, DU-145, PC-3 and
LNCaP cells. The concentration was calculated by a standard curve using known amounts of CXCR3A or CXCR3B plasmids. Histogram represent
mean values (+/-s.d.) of more than three separate experiments (*P < 0.05 compared to RWPE-1). (C) Ratio of CXCR3A vs. CXCR3B mRNA
expression. The calculation was based on the data in (B). DU-145 and PC-3 cells showed higher ratio than RWPE-1 cells. (D) Protein expression of
total CXCR3 and CXCR3B in RWPE-1, DU-145, PC-3 and LNCaP cells. (E) Quantification of protein expression in prostate cancer cells. Histogram
represent mean values (+/-s.d.) of three separate experiments (*P < 0.05 compared to RWPE-1).
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(RWPE-1), all tested prostate cells expressed similar
level of total CXCR3 at both mRNA and protein levels
(Figure 3A, D and 3E). Looking at the CXCR3 splicing
isoform expression, in contrast to RWPE-1 cells, in
which CXCR3B was basically the only splice variant,
both CXCR3A and CXCR3B were expressed at near
equivalent levels in the two invasive and metastatic
prostate cancer cell lines, DU-145 and PC-3, but not in
the LNCaP cells (Figure 3B and 3C). As a result,
CXCR3B protein expression reduced to approximately
50% in DU-145 and PC-3 cells compared to RWPE-1
cells (Figure 3D and 3E).
As epithelial cells can express the CXCR3-binding
chemokines, we queried for potential autocrine stimula-
tory loops. RNA and protein levels of two known
ligands of CXCR3, CXCL10/IP10 and CXCL11/IP9 were
down-regulated in the tumor lines. CXCL4/PF4 was up-
regulated in DU-145 and PC-3 cells but not in LNCaP
cells (Additional file 2). Another ligand CXCL9/MIG
showed overall negligible levels of mRNA expression.
CXCR3 is a seven-transmembrane receptor, whose
localization plays a key role in its activity. The cellular
localizations of CXCR3 and CXCR3B were examined in
RWPE-1, DU-145, PC-3 and LNCaP cells by flow cyto-
metry, in which CXCR3 or CXCR3B proteins were
labeled by specific antibodies with or without prior cell
permeabilization; these detections represent total protein
and membranous protein, respectively (Additional file 3)
(examination of the CXCR3A isoform is not currently
possible as there are no available antibodies that are suf-
ficiently specific for CXCR3A due to near complete
overlap in sequence). The fluorescence-positive cells
revealed both CXCR3 or CXCR3B were more abundant
in the cytosolic location in DU-145 and PC-3 as
opposed to surface locale in RWPE-1 and LNCaP cells,
which is similar to the CXCR3 localization in human
metastatic prostate carcinoma tissues (Figure 1A
enlarged boxes). This suggests that CXCR3/CXCR3B
internalization and turnover might be occurring in
advanced prostate carcinoma cells, indicative of auto-
and para-crine stimulation.
CXCR3-chemokine-induced cell motility and
invasion is elevated in prostate cancer cells
via PLCb3 signaling pathway
With the above data linking CXCR3 upregulation to
prostate cancer progression and the switch to expressing
both isoforms, we queried how this affects cell behaviors
[18,25,39]. Even though CXCR3 has been reported as a
cell growth regulator in select cancers [37,38,40],
CXCR3-chemokines did not alter the cell proliferation
in the prostate cancer lines tested (data not shown).
Therefore, we looked at cell motility induced by CXCR3
signal transduction. Since CXCL4/PF4 and CXCL10/
IP10 represent the main CXCR3 ligands found during
platelet degranulation and thus any hemorrhage and
deep in reactive/wounded stromal compartment respec-
tively, we examined functions of these two CXCR3 che-
mokines on prostate carcinoma cell functioning. Due to
low basal and growth factor stimulated cell motility and
invasiveness (data not shown), LNCaP cells were not
used for chemokine-induced cell motility and invasion
examination in the following studies. As expected,
CXCR3 ligands inhibited cell motility in RWPE-1 cells.
Interestingly, CXCL4/PF4 and CXCL10/IP10 promoted
cell motility in both DU-145 and PC-3 cells in vitro
(Figure 4A). CXCR3 blocking antibodies prevented che-
mokines-induced cell motility significantly in DU-145
cells suggesting that cell motility was induced specifi-
cally through CXCR3 (Additional file 4). Since cancer
cell motility is tightly related to cancer invasion, we next
examined DU-145 and PC-3 invasiveness in a CXCR3-
chemokine environment. Unsurprisingly, the CXCR3
chemokines blocked RWPE-1 cell invasion through a
Matrigel matrix barrier, but increased the invasiveness
of both prostate cancer lines (Figure 4B). These data
suggest that activated CXCR3 signaling may drive pros-
tate cancer cells invasion and metastasis.
CXCR3 is a G-protein-coupled receptor and the two
different isoforms appear to activate different down-
stream signaling pathways. CXCR3A and CXCR3B both
activate PLCb and induce downstream intracellular Ca++
flux, which activates μ-calpain to loosen cell-substratum
adhesion and promote cell motility. CXCR3B signaling
also triggers PKA, known as cAMP-dependent protein
kinase, which in turn inhibits m-calpain activation, pre-
venting tail release and blocking cell migration
[18,19,24,25,41-43]. We had previously shown that inhi-
biting m-calpain limits prostate cancer cell invasion and
metastasis in xenograft models as well as in vitro
[44,45]. To dissect which signaling pathway was domi-
nant in prostate cancer cells leading to cell migration,
we queried these intermediaries. Firstly, as there are
many isoforms of PLCb, PLCb3 was chosen due to its
predominant expression in the prostate cell lines (data
not shown). PLCb3 protein expression was reduced to a
quarter of its level by siRNA in DU-145 cells as the test
line (Figure 5A). With markedly reduced PLCb3 expres-
sion, CXCR3-mediated cell motility and invasiveness
both decreased dramatically in DU-145 cells, suggesting
that CXCR3 promoted cell migration and invasion
through PLCb3 pathway (Figure 5B and 5C). Further-
more, when CXCR3B was downregulated by siRNA
transfection in DU-145 cells without affecting CXCR3A
expression, no changes of cell motility were observed
(Additional file 5), indicating that the activation of cell
migration was mainly a result of PLCb3 activity through
CXCR3A signaling pathway in DU-145 cells.
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Inhibition of cell motility and invasion in normal prostate
cells correlated with m-calpain activity blockage
To examine whether the cell motility inhibitory signal
pathway(s) via CXCR3B is active or not in normal and
cancerous prostate cells, cAMP was analyzed after
ligand exposure. Prostate cancer cells showed higher
cAMP at an overall level than normal cells. In RWPE-1
cells, CXCL4/PF4 and CXCL10/IP10 markedly elevated
cAMP amount. In contrast, neither of these two
CXCR3 chemokines changed the elevated cAMP abun-
dance in DU-145 cells but reduced to some extent the
very elevated levels in PC-3 cells (Figure 5D); however,
this was on the background of greatly elevated basal
cAMP making changes in levels less relevant than
absolute levels which were higher than even stimulated
levels in RWPE-1 cells. Since μ-calpain and m-calpain
are regulated by PLCb/Ca++ and cAMP/PKA pathways
respectively, which play direct and essential roles in
cell migration regulation, we next examined calpain
activities in these cells. Total calpain activity (from
both μ-calpain and m-calpain) did not change much in
RWPE-1 cells after CXCR3 chemokine treatment.
Interestingly, m-calpain activity significantly decreased
with CXCL4/PF4 and CXCL10/IP10 in these normal
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Figure 4 CXCR3 chemokine promoted prostate cancer cell motility and cell invasion. (A) cell motility and (B) cell invasiveness in RWPE-1,
DU-145 and PC-3 cells after 5 nM EGF or 1 μg/ml chemokine treatment for 16 hrs. The moving distance (arbitrary units, A.U.) in cell motility
assay was measured by the pixel changes in ImageJ after 16 hrs. Cell invasiveness was evaluated by the number of invaded cells after 16 hr
treatment in Matrigel invasion chamber system. Histogram represent mean values (+/-s.d.) of more than three separate experiments each in
triplicate (*P < 0.05).
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prostate cells (Figure 5E), suggesting that inhibition of
cell motility and invasiveness from CXCR3 chemokines
is a result of m-calpain activity reduction. More impor-
tantly, this activity decrease was not a result of m-cal-
pain protein expression level change (Additional file 6).
Since there is no increase of cAMP amount after
CXCL4/PF4 or CXCL10/IP10 treatment in the prostate
cancer cell lines, m-calpain activities remained at same
levels compared to the untreated cells (Figure 5E), sug-
gesting that inhibition of cell migration via the
CXCR3B pathway was not active in prostate cancer
cells.
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Figure 5 CXCR3 chemokine induced cell motility and invasion via PLCb3 signaling pathway in prostate cancer cells and blocked cell
motility by m-calpain activity inhibition in normal cells. (A) PLCb3 was significantly knocked down in DU-145 cells by siRNA. Protein
expression was quantified by ImageJ and normalized to GAPDH. Histogram represent mean values (+/-s.d.) of three separate experiments (**P <
0.05). CXCR3-chemokine-induced (B) cell motility and (C) cell invasiveness in DU-145 cells reduced after PLCb3 downregulation. Histogram
represent mean values (+/-s.d.) of three separate experiments (*P < 0.05, compared to untreated controls; **P < 0.05, compared to siControl
group). (D) cAMP amount in RWPE-1, DU-145 and PC-3 cells after chemokine induction. Histogram represent mean values (+/-s.d.) of three
separate experiments (*P < 0.05 compared to untreated controls). (E) Calpain activity in RWPE-1, DU-145 and PC-3 cells after chemokine
treatment. Calpain activity was quantified by fluorescent intensity of calpain substrate. The signal intensities of untreated samples were set as 1
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CXCR3B overexpression in DU-145 cells blocked
chemokine-induced cell motility and invasion via m-
calpain activation inhibition
CXCR3B was found to be the primary CXCR3 isoform
in prostate normal tissue and prostate epithelial RWPE-
1 cells. However, in prostate carcinoma tissues and cell
lines, not only was CXCR3A highly expressed but the
level of CXCR3B was reduced. Thus, a question remains
as to whether the reduced expression of CXCR3B was
operative rather than the novel expression of CXCR3A.
To understand better about CXCR3B signaling in pros-
tate cancer cells, the CXCR3B splice variant was overex-
pressed in DU-145 cells up to 2 fold at the protein
expression level (Figure 6A). Overexpression of
CXCR3B in DU-145 cells did not change CXCR3A or
CXCR3-ligands expression levels at a mRNA level or
cellular localization of CXCR3 (Figure 6B, C and data
not shown). No proliferation rate alteration was
observed in these cells either (data not shown). How-
ever, in these DU-145 cells with CXCR3B overexpres-
sion, chemokines inhibited cell motility and invasion
(Figure 6D and 6E), suggesting that prostate cancer cell
motility and invasiveness elevation was due to a lack of
CXCR3B signaling at least in part in addition to
CXCR3A expression.
However, to examine whether CXCR3 expression still
contributes to motility, PLCb3 was down-regulated by
siRNA and cell motility was measured. Interestingly,
DU-145 cells with CXCR3B overexpression and PLCb3
knockdown showed a further reduction of cell motility
compared to cells with CXCR3B overexpression only
(Figure 7A), suggesting that PLCb3 was still active in
DU-145-CXCR3BOX cells, but that CXCR3 signaling
through PLCb3 was contributing positively to migration;
this might be occurring through an endogenous
CXCR3A signal. We observed that cell motility and
invasion was inhibited in both RWPE-1 and DU-
CXCR3BOX prostate cancer cells, and this inhibition
is due to upregulation of cAMP level and m-calpain
activity reduction in RWPE-1 cells (Figure 4 and 6).
Therefore, we asked the question that whether DU-
CXCR3BOX cells activated same signaling pathway
mainly through CXCR3B to block cell motility and inva-
siveness. Unsurprisingly, CXCL4/PF4 and CXCL10/IP10
treatment increased cAMP levels in DU-CXCR3BOX
cells (Figure 7B), which blocked m-calpain activity
(Figure 7C). These data indicate that even in the face of
promigratory signaling from CXCR3A, high levels of
CXCR3B signaling can override this to inhibit cell
movement.
Discussion and conclusion
Our findings, for the first time, illustrate that CXCR3
isoform switching may impact tumor dissemination,
shifting a usually anti-migratory ‘stop’ signal into a pro-
migratory and invasive “go” signal. Previous studies had
identified distinct signaling pathways by which this
receptor could actuate diametrically opposite motility
behaviors. Both CXCR3A and CXCR3B activate PLCb
downstream of heterotrimeric G proteins. PLCb hydro-
lyzes phosphatidylinositol 4,5-bisphosphate (PIP2), gen-
erating two products: inositol 1,4,5-trisphosphate (IP3),
a universal calcium mobilizing second messenger; and
diacylglycerol (DAG), an activator of protein kinase C
(PKC). IP3 induces intracellular Ca++ flux, which acti-
vates μ-calpain and results in cell motility induction by
lessening adhesion [25]. PKC plays a positive role in
ERK activation and followed by m-calpain phosphoryla-
tion and activation. In a word, CXCR3 signals from
PLCb activity promotes cell migration unless the cell
detaches due to the cleavage of a predominant b3 integ-
rin as in endothelial cells [46]. A unique signal transduc-
tion path via CXCR3B leads to an accumulation of
cAMP. With CXCR3B signals, PKA, known as cAMP-
dependent protein kinase, is activated which inhibits
m-calpain activation and blocks cell migration
[18,19,24,25,41-43]. Thus, the cell outcome is deter-
mined by the balance between these two pathways and
the cell’s overall adhesiveness and complement of
integrins.
The findings in tissue and epithelial cells (RWPE-1)
suggest that CXCR3B is the dominant splice variant in
normal human prostate tissues and these cells. CXCL4/
PF4 and CXCL10/IP10 inhibited RWPE-1 cell motility
and invasiveness mainly via cAMP upregulation and m-
calpain activity reduction through CXCR3B. In these
normal cells, PLCb3 was still active because intracellular
Ca++ flux could be induced and total calpain activity
increased, suggesting that CXCL10/CXCL4-CXCR3B
axis also turned on pro-migratory signals. However, μ-
calpain and m-calpain activity are both required for cell
motility as they act at distinct site in the cell [47];
hence, inhibiting m-calpain to prevent rear de-adhesion
blocked RWPE-1 migration and invasion and was domi-
nant over the de-adhesion-mediated motility.
In invasive and metastatic prostate cancer cells (DU-
145 and PC-3), CXCR3A and CXCR3B are both
expressed with CXCR3B being reduced in level com-
pared to the normal prostate cell line. CXCR3 ligands,
CXCL10/IP10 and CXCL11/IP9 were downregulated in
all tested prostate cancer cells and CXCL4/PF4 were
elevated in DU-145 and PC-3 cells (Additional file 2).
These ligand expression data suggest that CXCL10/IP10
and CXCL11/IP9 might be an operative ligand in nor-
mal prostate cells, while CXCL4/PF4 may play a role in
the invasive and metastatic cells, though definitive test-
ing of such awaits further testing. Our data revealed
that CXCL4/PF4 and CXCL10/IP10 both promoted
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migration and invasiveness in vitro in prostate cancer
cells. This motility was blocked by CXCR3 antibody sig-
nificantly and CXCR3B antibody mildly in DU-145 cells
(Additional file 4 and data not shown), indicating that
cell motility activation in prostate cancer cells was due
mainly to CXCR3A but that CXCR3B may also contri-
bute. We must note that Lasagni et al. reported
CXCR3B isoform in microvascular endothelial cells and
suggested CXCL4/PF4 is a CXCR3B-specific ligand [19].
However, other later work suggests CXCL4/PF4 induces
activated T lymphocytes migration through CXCR3A
signaling [26]. In any case at the higher levels of ligand,
CXCL4/PF4 appears to activate both isoforms. In DU-
145 and PC-3 cells, cAMP activity was sustained at a
high level and no further upregulation of cAMP was
able to be detected by any CXCR3 chemokine treat-
ment, resulting in no inhibition of m-calpain via
CXCR3B pathway. This high level of cAMP is correlated
with upregulated PKA activity in DU-145 and PC-3 cells
compared to RWPE-1 cells (Additional file 7), and thus
is likely not further activated by CXCR3B signaling. In
summary, in these prostate cancer cells, PLCb3 plays an
essential role on cell migration promotion which may be
through μ-calpain activation. However, CXCR3B-
induced inhibitory signals were not effective.
We then queried whether the key change was expres-
sion of CXCR3A or also a quantitative decrement in
CXCR3B. When exogenous CXCR3B was expressed in
DU-145 to bring the balance of CXCR3 isoform back,
even higher than RWPE-1 cells, cell motility and inva-
siveness decreased, recapitulating the behavior of
RWPE-1 cells (this was confirmed in two distinct indivi-
dual colons). The inhibition in these DU-145-
CXCR3BOX cells is a result of increased cAMP after
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CXCR3 chemokine induction, following by m-calpain
activity inhibition, which is the same pathway that limits
dissemination in RWPE-1 cells. The migratory effects of
CXCR3 isoform signaling in LNCaP cells would be of
interest but as the basal motility levels of these cells is
very low, this line of investigation is not productive.
Based on the analysis of CXCR3 ligand expression in
LNCaP, very low levels of all the ligands suggest the
CXCR3 signaling activation may not be an essential role
in cell migration regulation in this line. The other
aspect, downregulation of CXCR3A to restore a quanti-
tative excess of CXCR3B was not accomplished as the
complementary molecules to downregulate this isoform
would also recognize the CXCR3B mRNA. Even in the
absence of this validation, the regulation of the balance
of CXCR3 splicing variants still could be a key factor for
prostate cancer to become motile and invasive. The dif-
ferences of CXCR3 receptor and ligand expression in
various prostate cancer cell lines might be a result from
metastatic organ specificity [38]; however, immunohisto-
chemistry analysis of a limited set of prostate metastases
indicated that CXCR3 expression is not organ selective
at least to a significant degree (Additional file 1). The
integrity and heterogeneity of CXCR3 expression and
regulation in cancer require further investigation.
It remains to be determined whether matrix remodel-
ing, in addition to motility alteration, regulates invasive-
ness in response to CXCR3 signaling. As an initial
examination of matrix alterations, we checked MMP2
and MMP9 expression levels, which have been shown to
be regulated by CXCR3 signals [12,48]. Interestingly,
RWPE-1 cells exhibited the highest levels of MMPs
among the tested cells and both MMP2 and MMP9
RNA levels were almost negligible for the prostate can-
cer cells (Additional file 8A). With CXCL4 and CXCL10
treatment, MMP2 expressions dramatically increased in
RWPE-1 and LNCaP cells; however, even with increase,
MMP2 expressions in LNCaP cells were still low.
MMP9 was mainly upregulated in PC-3 and LNCaP
cells but this increase could be negligible due to a low
absolute expression (Additional file 8B). These data sug-
gest CXCR3-induced MMP elevation may not play a cri-
tical role in the regulation of prostate cancer cell
motility. This is consistent with our earlier findings that
while matrix proteases were required for DU-145 inva-
siveness in vitro and dissemination in vivo [49,50], their
regulation was not a major regulator of these properties.
Our results from in vivo studies found that more cells
in localized and metastatic prostate tumors expressed
CXCR3 compared to normal prostate tissue (Figure 1).
Interestingly, this upregulation of CXCR3 was also
observed in breast cancer wherein it was correlated to
poor patient survival [31], suggesting that CXCR3 could
be an important pro-dissemination signal for cancer
dissemination, invasion and metastasis. Primary localiza-
tion of CXCR3 in normal prostate tissues was membra-
nous. In contrast, CXCR3 seems to have relocalized
from the cell membrane to the cytosol in prostate
tumors, as was also detected in tissue-cultured cell lines
(Figure 1 and Additional file 3); this could reflect inter-
nalization/downregulation based on autocrine/paracrine
signaling or hint at a distinct signaling function from
intracellular organelles. Other than prostate epithelial
cell expressing CXCR3, some prostate stromal cells as
well as endothelial cells also showed CXCR3 expression
in prostate cancer tissues. These stromal cells may
experience an inflammatory milieu, because an increase
of CXCR3 was also been observed in PIN samples (data
not shown). In cancer samples, mononuclear cell infil-
trate may also induce CXCR3 upregulation to some
extent. Endothelial cells are known to have only
CXCR3B expression, which plays a role in anti-angio-
genesis [18], suggesting that upregulation of CXCR3 in
endothelial cells in prostate cancer could be used to
limit cancer angiogenesis. More important and novel in-
vivo finding from out studies was the obvious switch of
CXCR3 splicing isoform in prostate cancer. The obser-
vation that CXCR3A was upregulated and CXCR3B was
downregulated in localized and metastatic prostate can-
cer compared to normal prostate tissues suggested that
this switch was not only observed in tissue-derived cell
lines but also the reality in cancer samples, which may
account for prostate cancer dissemination, invasion and
metastasis.
Several study in animal model have reported using a
CXCR3 antagonist, AMG487 or knockdown of CXCR3
to inhibit breast, colon, osteosarcoma and melanoma
cell metastasis [31,34-37]. In addition, Cambien et al.
recently showed that AMG487 effectively blocked color-
ectal cancer dissemination to lung but not to liver [38],
suggesting that in vivo CXCR3-promoted cancer metas-
tasis could be organ selective. In these studies it is not
clear whether there is also a switch in CXCR3 splicing
variants. Based on our cellular research, we believe
AMG487 or siRNA mainly inhibit CXCR3 pro-migra-
tory function by blocking CXCRA pathways which
could be a main signaling transduction in cancer. How-
ever, since CXCR3B accounts for anti-migratory and
also anti-angiogenesis signals, it would be preferential to
target CXCR3A and not both isoforms.
In conclusion, our data suggest that prostate cancers
subvert a ‘stop’ signal into a progression signal by regu-
lating CXCR3 splicing. This is not a complete switch
but a quantitative realignment. When we increase the
balance of primary CXCR3 splice variant back towards
CXCR3B in prostate cancer cells (DU-145), the stop sig-
nal is retained. Therefore, expression pattern of
CXCR3A and CXCR3B in human prostate cancer could
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be a biomarker for invasive prostate cancer diagnosis.
More importantly, our study has implications for ratio-
nale approaches to limiting prostate cancer invasion and
metastasis.
Materials and methods
Cell culture and Tissue Microarrays
American Type Culture Collection (ATCC) cell lines,
RWPE-1, DU-145, PC-3 and LNCaP were cultured in
medium recommended by the supplier. All cells were
incubated at 37°C in 5% CO2. The Tissue Microarray
was produced by the University of Pittsburgh Prostate
Tumor Bank from de-identified tumor specimens con-
sented for research at time of treatment. Use of these
tissues was approved the University of Pittsburgh Insti-
tutional Review Board.
Quantitative real-time PCR
Total RNA was extracted from cells by RNEasy Kit
(Qiagen, CA) and cDNA was reverse-transcribed by
QuantiTect (Qiagen, CA). SYBR Green RT-PCR was
performed (Stratagene, CA) with following primers:
CXCR3: forward 5’-ACACCTTCCTGCTCCACCTA-3’;
reverse 5’-GTTCAGGTAGCGGTCAAAGC-3’ CXCR3A:
forward 5’-AGCCCAGCCATGGTCCTTGA-3’; reverse
5’-CTGTAGAGGGCTGGCAGGAA-3’ CXCR3B: for-
ward 5’-TGCCAGGCCTTTACACAGC-3’; reverse
5’-TCGGCGTCATTTAGCACTTG-3’ CXCL4: forward
5’-GCGCTGAAGCTGAAGAAGAT-3’; reverse 5’-GT
CCGGCCTTGATCACCT-3’; CXCL10 forward 5’-AAG-
GATGGACCACACAGAGG-3’; reverse 5’-AGCAGG
GTCAGAACATCCAC-3’; CXCL11 forward 5’-ATG
AGTGTGAAGGGCATGGC-3’; reverse 5’-TCACTG
CTTTTACCCCAGGG-3’; MMP2 forward 5’AACA-
CAGCCTTCTCCTCCTG-3’; reverse 5’- CACCTACAC-
CAAGAACTTCC-3’; MMP9 forward 5’- CCT CGC
CCT GAA CCT GAG C -3’; reverse 5’-GCTCTGA
GGGGTGGACAGTG-3’ and GAPDH forward 5’-GAGT
CAACGGATTTGGTCGT-3’; reverse 5’-TTGATTTTG-
GAGGGATCTCG-3’. GAPDH was used for control and
normalization.
Cell migration assay
Cell migration was performed as previously described
[18]. Cell monolayer was allowed to become quiescent
in medium with 0.1% dialyzed fetal bovine serum for
16h. Then cells were scraped to make a denuded area
and treated with EGF (5 nM), CXCL10/IP10 (1 μg/ml)
or CXCL4/PF4 (1 μg/ml) (PeproTech, NJ) for 16 h.
Photographs were taken at 0 and 16 h, and the relative
distance migrated by the cells from the edges was ana-
lyzed by ImageJ.
Cell invasion assay
Cell invasion assay was performed by BD BioCoat
Growth Factor Reduced Matrigel Invasion chamber sys-
tem (BD Biosciences, MA) according to the manufac-
ture’s protocol. In brief, cells were seeded in the insert
as 2.5 × 104 with quiescent medium for each assay.
Then chemokines were added into the bottom chamber
and cells were incubated for 48 hrs. After incubation,
base membrane of the chamber was cut and cells were
stained by DAPI (Sigma, MO). The total number of
invaded cell was counted.
cAMP measurement
cAMP levels were assessed using a commercially avail-
able colorimetric kit (Calbiochem, NJ). In brief, 2 × 105
cells were seeded in a well of 6-well plate and quiescent
for 24 hrs. Then cells were treated with 5 nM EGF or 1
μg/ml chemokines for 5 hrs, lysed and cAMP levels
were measured according to the manufacture’s protocol.
Calpain activity assay
In vivo calpain activity was determined by using the
membrane permeable substrate t-BOC-LM-CMAC
(BOC) (Sigma, MO). In brief, cells were incubated with
1 μg/ml chemokines for 1 hr and then 25 μM BAPTA/
AM (Sigma, MO) for 10 min to chelate calcium in cells
to detect only m-calpain activity. The cells were further
incubated with 25 μM BOC for 20 min. The cleavage of
BOC by calpain was measured using a fluorescence
spectrometer.
Immunohistochemistry
Prostate normal and tumor tissue microarray (TMA)
was from tissue bank, University of Pittsburgh with IRB
committee approval. TMA for immunohistochemical
analysis were incubated with appropriately diluted pri-
mary antibody and secondary antibody, after antigen
retrieval (BioGenex, CA). Antigen staining was per-
formed using diaminobenzidine (DAB), then counter-
stained with Mayer’s hematoxylin.
In situ hybridization
The oligonucleotide probe for detecting CXCR3 mRNA
(5’ CGT AGA AGT TGA TGT TGA AGA GGG CAC
CTG 3’), CXCR3A mRNA (5’ GGT GGT CAC TCA
CCT CCA GGA CCA TGG 3’) and CXCR3B mRNA
(5’CTC TTT TGT GAT TGA GTC TGA TTT AG 3’)
were labeled with DIG oligonucleotide. DIG-tailed sense
CXCR3, CXCR3A and CXCR3B mRNA probes were
used as negative controls. In situ hybridization was per-
formed as previously described [51]. Briefly, sections
were deparaffinized, rehydrated and then hybridiza-
tion was performed at appropriate temperatures for
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overnight. After hybridization, nonhybridized probes
were removed by high stringency washes. The sections
were incubated with anti-DIG-labeled antibody conju-
gated with alkaline phosphatase and the signal was col-
orized with BCIP/NBT (Roche Applied Science,
Germany).
Plasmid or siRNA transfection
Cells were seeded as 2 × 105 cells per well of 6-well
plate. After 16 hrs, cells were transfected with 2 μg of
pTarget-CXCR3B plasmids and 10 μl of Lipofecta-
mine2000 (Invitrogen, CA) according to the manufac-
turer’s protocol. After 24 hr transfection, stable clones
were selected and isolated in DU-145 medium supple-
mented with 1000 μg/ml G418. siRNA targeting
CXCR3B (Invitrogen, CA), PLCb3 (Santa Cruz Biotech-
nology, CA) or control siRNA (Santa Cruz Biotechnol-
ogy, CA) were delivered into the cell by the same
protocol with Lipofectamine2000.
Immunoblotting
Cells were lysed by RIPA buffer, separated on SDS
PAGE, transferred to a nylon membrane, and then
immunoblotted for CXCR3 (R&D Systems, MN),
CXCR3B (Protein Tech, IL), CXCL4 (R&D Systems,
MN), CXCL10 (PeproTech, NJ), CXCL11 (PeproTech,
NJ), PLCb3 (Santa Cruz Biotechnology, CA), or GAPDH
(Sigma, MO). The blots were visualized using chemilu-
minescent substrate for HRP (Thermo Scientific, IL) and
X-ray film processor (AFP imaging, NY).
Statistical analysis
All experiments were performed at least three times,
each in triplicate with mean ± s.d. being presented. Sta-
tistical significance was determined using the Student t-
test with statistical significance assessed with a probabil-
ity value less than 0.05.
Additional material
Additional file 1: CXCR3 expression levels in prostate cancer
metastases were not organ specific (*P > 0.5). The analyses were
based on data shown in Figure 1B. Metastatic prostate cancer localized
in different organs was grouped and graphed with percentages of
CXCR3-positive cells, including 5 lymph node metastases, 4 liver
metastases, 2 lung metastases and 1 adrenal metastasis. Statistical
analyses were not available in comparison to adrenal group due to a
small sample size.
Additional file 2: CXCR3 chemokine expression in normal and
prostate cancer cells. CXCR3 chemokine expression in normal and
prostate cancer cells. (A) Chemokine mRNA expression in normal and
prostate cancer cells. Ligand mRNA expression was normalized to
GAPDH mRNA expression. Histogram represents mean values (+/-s.d.) of
three separate experiments (*P < 0.05 compared to RWPE-1 cells). (B)
Chemokine protein expression in normal and prostate cancer cells.
Additional file 3: CXCR3 localization in normal and prostate cancer
cells detected by flow cytometry. (A) Cells were collected and treated
with or without PBST (PBS with 0.5% Tween-20) to permeablize cell
membrane, then further stained with CXCR3 or CXCR3B antibody for
flow cytomery. Black: IgG only; Red: surface CXCR3; Green: surface and
intracellular CXCR3. The graphs are representative results from more than
three experiments. (B) Quantitative analysis of CXCR3 and CXCR3B
localization in prostate cells based on graphs showing in (A). Histogram
represents mean values (+/-s.d.) of three separate experiments (*P < 0.05
compared to RWPE-1 cells).
Additional file 4: CXCR3-chemokine-induced cell migration was
blocked by CXCR3 antibody in DU-145 cells. Cells were treated with
chemokine with or without CXCR3 blocking antibody. Cell migration was
measured by the distance change (quantified by pixel) in 16 hrs.
Histogram represents mean values (+/-s.d.) of three separate experiments
(*P < 0.05).
Additional file 5: CXCR3B downregulation did not change DU-145
cell migration. CXCR3B was knocked down by siRNA and evaluated at
(A)mRNA and (B) protein expression levels. Histogram represents mean
values (+/-s.d.) of three separate experiments (*P < 0.05).(C) No change
of cell migration was observed after CXCR3B downregulation. Cell
migration was evaluated by the distance change (quantified by pixel) in
16 hrs. Histogram represents mean values (+/-s.d.) of three separate
experiments.
Additional file 6: m-calpain expression in prostate normal and
cancer cells. No changes of m-calpain expression were observed after
chemokine treatments (A) in normal and prostate cancer cells and (B) in
DU-145 and DU-145 CXCR3 overexpressing cells. Each experiment was
repeated with similar results.
Additional file 7: PKA activity in prostate normal and cancer cells.
PKA activity in prostate cancer cells was assessed by using a
commercially available PepTag Assay kit (Promega, WI). Higher PKA
activity was found in prostate cancer cells than normal prostate epithelial
cells. Graph represents mean values (+/-s.d.) of three separate
experiments (*P < 0.05).
Additional file 8: MMP mRNA expression in prostate normal and
cancer cells. (A) MMP2 and MMP9 mRNA expression in prostate normal
and cancer cells (*P < 0.05 compared to RWPE-1 cells). MMP mRNA
expression was normalized to GAPDH mRNA expression in each cell
lines. (B) MMP2 and MMP9 mRNA expression after CXCR3 chemokine
treatment in prostate normal and cancer cells. The mRNA expression
levels in untreated RWPE-1 cells were set as 1. Graphs represent mean
values (+/-s.e.m.) of three separate experiments each in triplicate (**P <
0.05 compared to untreated within the group).
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